Sign up USA
Proactive Investors - Run By Investors For Investors
EPIC: AVO
Market: AIM
Sector: Health Care, Equipment & Services
Phone: +44 (0)203 617 8728
Address: Third Floor, Clearwater House, 4-7 Manchester Street, London W1U 3AE.
Website: www.advancedoncotherapy.com/Home.aspx
Advanced Oncotherapy

Advanced Oncotherapy

Advanced Oncotherapy plc is a UK-based company focused on delivering a cost-effective proton-based radiotherapy solution called LIGHT. Based on ground-breaking technology developed and tested at world renowned CERN in Switzerland, the LIGHT system delivers an integrated proton radiotherapy system to treat cancer. The uniqueness of LIGHT means that it is possible to treat patients in the centre of any major city in the world at an affordable price.

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Advanced Oncotherapy


Advanced Oncotherapy Snapshot

Our sole focus is to develop technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to healthy tissues. Our goal is to help healthcare providers and hospitals expand their repertoire of treatments to ensure clinicians and patients have choices. Advanced Oncotherapy's aim is to cost-effectively deliver the next generation of proton therapy which is clinically superior to the currently available alternative radiation therapies.

Advanced Oncotherapy plc has its head office in London, UK, an R&D/ADAM facility located on the campus of CERN, Geneva, Switzerland, and a manufacturing plant, clinical research and clinician training facility in Syracuse, USA.

Advanced Oncotherapy plc is a public limited company in England and Wales; company number 05564418 with registered offices on Level 17, Dashwood House, 69 Old Broad Street, London, EC2M 1QS. The Company’s shares are listed on the AIM market of the London Stock Exchange under the symbol AVO.L

Cancer care

Cancer is a condition characterised by uncontrolled cell proliferation. It is a leading cause of mortality among all diseases. 22 million people are currently living with cancer worldwide. 8 million people are likely to die as a result of cancer per year. It is responsible for more deaths globally than AIDS, malaria and tuberculosis combined.

With 16 million new cancer cases expected per year by 2020, cancer is projected to become the largest share of drug spend.


Today, survival rates are higher than ever before – in the UK, two in every four people will beat cancer. This is incredible progress when considering that in the 1970s less than a quarter of people survived. But there is more to be done. That is why at Advanced Oncotherapy we are focused on defeating cancer – and with our partners and stakeholders, we are going to accelerate progress so that more lives can be saved.

Radiation therapy


Radiation therapyMethods of cancer treatment include surgery, medication and radiotherapy. Depending on the size, location and type of cancer, each of the different approaches may be used in isolation or in conjunction with the others:

Surgery; is the direct treatment approach that aims to remove the tumour. In many cases, surgery might be the preferable option but close proximity to delicate organs prevents surgical removals. Besides, surgery is usually not an option for elderly patients. Recovery times can be long and, from a cost perspective, surgery is in most cases less desirable than alternative treatments.
Medication; a key characteristic of cancer cells is their rapid division, which outpaces that of most healthy cells. Cancer medicines try to exploit this feature through the general destruction of fast-dividing cells. The disadvantage is that healthy cells that also divide fast (such as hair cells) are attacked by cancer drugs. These drugs are also highly poisonous, distributed in the whole body through the bloodstream and cancer cells may develop resistance.
Radiation; it damages the genetic material in cancer cells and destroys their ability to reproduce by using an external source of energy. It is highly effective in the treatment of tumours present in areas which could not be accessed using traditional surgery methods. In contrast to medication treatments such as chemotherapy or hormone treatment, radiotherapy is a local treatment, limiting both desired and undesired effects to the irradiated tissue area.
At Advanced Oncotherapy, we are focused on radiation therapy because:

Radiation therapy has been used for more than 80 years and it has a successful track-record in curing cancer. It is estimated that of those patients treated in the EU, over 65% of patients will receive some form of radiotherapy, making radiotherapy one of the most important treatment modalities;
Radiation therapy treatment is non-invasive, can be done without anaesthesia and the patient is usually able to leave the hospital the same day;
It has significant cost benefits. As a complement to its medical effectiveness, radiotherapy offers clear cost advantages over other treatment methods. The global cost of radiation therapy is estimated at less than 10% of cancer drug costs. The cost of open cancer surgery is 2x that of treating cancer with radiotherapy, while the drugs required for chemotherapy can cost 3-5x as much.

Proton therapy


Most conventional radiotherapy treatments use beams of X-rays to treat tumours. X-rays are high-energy waves made of photons, which are a form of electromagnetic radiation. However the beams do not discriminate between cancerous and normal tissue. Although the radiation beams are focused on a tumour, so the dose to the surrounding tissues is minimised, there will inevitably be some potential damage, leading to short or long-term side effects, including the risk of developing secondary malignancies. While these side effects are obviously not ideal for cancer patients at any age, they can be particularly harmful for children as their bodies are still developing and they are more susceptible to the effects of radiation. Children are also more at risk of developing a secondary cancer later in life, caused by their early exposure to radiation.

Recent advances in radiation therapy technologies have focused clinicians on further improving the ability to target the radiation dose more precisely at cancer cells while minimising the exposure to healthy tissue.

The most significant industry developments in radiation therapy is the development of proton therapy, a highly-targeted type of radiotherapy that can treat hard-to-reach cancers with a lower risk of damaging surrounding tissues and causing side effects. This is because protons stop once they hit their target, whereas X-ray beams carry on through the body. Literature shows that proton therapy can cut down the risk of developing secondary malignancies by up to 50%.

For further information, click here

Proton therapy is widely accepted by physicians, governments and many insurers worldwide. It has been used for more than 50 years and in the hospital setting since 1990. As of December 2013, over 120,000 patients were treated worldwide in 45 centres worldwide.

While proton therapy systems have been recognised as a superior treatment modality, widespread treatment of common cancers has been impractical, due to the size and cost of proton therapy machines. This currently results in a lack of centres equipped with appropriate equipment, which in turn explains why today only 1% of cancer patients have benefited from proton therapy.

This is why at Advanced Oncotherapy, we are focused on a revolutionary proton therapy system that can be used and afforded by most people, not just by an exclusive minority. With the application of our new LIGHT technology, Advanced Oncotherapy is committed to deliver a significantly more cost effective, smaller 1, 2, or 3 room system to enable treatment with protons to become a financially viable treatment option.

 

 

 

 

 

Dr Mike Sinclair
Chief Executive Officer and Executive Chairman | Appointed: Jun. 2006 | Nationality: British

Skills and experience

Held a number of appointments at teaching hospitals in London; registrar in Psychiatry at the Maudsley Hospital and Institute of Psychiatry of London University; more than 40 years of experience in the healthcare business.

Current Appointments

Chief Executive Officer and Executive Chairman.

Previous Appointments

Founder and Chief Executive of Nestor Healthcare and Allied Medical Group Limited; Chairman and Founder of Lifetime Corporation Inc; Member of the Board of Overseers of the Tufts University School of Medicine; Chairman and Founder of US based Atlantic Medical Management LLP.

 

Nicolas Serandour
Chief Operating and Financial Officer | Appointed: Sep. 2014 | Nationality: French


Skills and experience

Over 15 years of experience in the investment banking industry; extensive experience providing strategic and financial advice to senior executives at leading healthcare companies internationally.

Current Appointments

Chief Operating and Financial Officer; on the Board of Totally Listed Ltd.

Previous Appointments

Previous experience at JPMorgan, Lehman Brothers and Lazard.

To read more click here

London Office

Advanced Oncotherapy plc
Third Floor
Clearwater House
4-7 Manchester Street
London
W1U 3AE
Phone: (+44) 0203 617 8728


US Office

Advanced Oncotherapy Americas Inc
CNY Biotech Accelerator Suite 1009
841 East Fayette Street
Syracuse
NY 13210

ADAM

Advanced Oncotherapy R&D facility
CH- 1211
Geneva 23
Switzerland

Please feel free to contact us on any topic anytime at [email protected]

Investor Relations [email protected]

Walbrook PR Ltd
4 Lombard Street
London EC3V 9HD
T: 020 7933 8780

Advanced Oncotherapy Timeline

Market Reports Including AVO

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC